Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FATE-NK100 + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FATE-NK100 | FATE NK100 | FATE-NK100 are donor-derived natural killer cells, which may induce cell death, and result in increased generation of inflammatory cytokines, thereby mediating an immune response against cancer cells (Cancer Res 2017;77(13 Suppl):Abstract nr 3752). | ||
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |